Richard Sykes, English biochemist and academic
Sir Richard Brook Sykes, (born 7 August 1942) is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation, and the trustees at King Edward VII's Hospital, and chancellor of Brunel University. As of June 2021, he is chair of the UK's Vaccine Taskforce, where he is responsible for overseeing the delivery of the COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.

In 1972, after gaining a first class bachelor's degree and a doctorate, both in microbiology, Sykes was appointed head of the Antibiotic Resistance Unit at Glaxo, where he helped develop the antibiotic ceftazidime. Subsequently he was recruited by the Squibb Institute, in the United States, where he then developed aztreonam, the first clinically effective monobactam, a term he coined in 1981 to describe a new group of monocyclic β-lactams produced by bacteria. He oversaw the merger of Glaxo with Wellcome, to form Glaxo-Wellcome in 1995 and became its chair two years later. He then oversaw the Glaxo Wellcome and SmithKline Beecham merger and held its chair until 2001.

His other appointments have included being rector of Imperial College from 2001 to 2008, chairman of NHS London from December 2008 to July 2010, vice-Chairman of Lonza Group until 2013, and chairman of Imperial College Healthcare from 2012 to 2018.